Ironwood Pharmaceuticals Inc [IRWD] stock is trading at $4.45, up 14.69%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IRWD shares have gain 26.06% over the last week, with a monthly amount glided 26.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] stock has seen the most recent analyst activity on September 09, 2024, when Leerink Partners initiated its Market Perform rating and assigned the stock a price target of $5. Previously, CapitalOne downgraded its rating to Equal Weight on August 08, 2024, and dropped its price target to $4. On January 17, 2024, Craig Hallum initiated with a Buy rating and assigned a price target of $21 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $20 on December 14, 2023. Jefferies initiated its recommendation with a Buy and recommended $21 as its price target on November 09, 2023. JMP Securities started tracking with a Mkt Outperform rating for this stock on September 28, 2023, and assigned it a price target of $22. In a note dated September 02, 2022, CapitalOne initiated an Overweight rating and provided a target price of $15 on this stock.
Ironwood Pharmaceuticals Inc [IRWD] stock has fluctuated between $3.06 and $15.70 over the past year. Currently, Wall Street analysts expect the stock to reach $8.5 within the next 12 months. Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] shares were valued at $4.45 at the most recent close of the market. An investor can expect a potential return of 91.01% based on the average IRWD price forecast.
Analyzing the IRWD fundamentals
Ironwood Pharmaceuticals Inc [NASDAQ:IRWD] reported sales of 378.42M for the trailing twelve months, which represents a drop of -19.47%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.07%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is -0.08 and Total Capital is 0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.78 points at the first support level, and at 3.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.13, and for the 2nd resistance point, it is at 5.80.
Ratios To Look Out For
For context, Ironwood Pharmaceuticals Inc’s Current Ratio is 3.62. Also, the Quick Ratio is 3.62, while the Cash Ratio stands at 1.79. Considering the valuation of this stock, the price to sales ratio is 2.16.
Transactions by insiders
Recent insider trading involved Davis Andrew, SVP, Chief Business Officer, that happened on Nov 18 ’24 when 5360.0 shares were sold. SVP, COO and CFO, Emany Sravan Kumar completed a deal on Nov 18 ’24 to sell 11001.0 shares. Meanwhile, Officer Davis Andrew bought 6090.0 shares on Nov 18 ’24.
